Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2008-05-27
2011-12-20
Canella, Karen (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S252300, C435S325000
Reexamination Certificate
active
08080388
ABSTRACT:
Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Preferred immunogenic polypeptides include gp100, her2
eu ECD-PD, ICD andM. tuberculosisantigens. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.
REFERENCES:
patent: 5066579 (1991-11-01), Reyes
patent: 5550214 (1996-08-01), Eberlein
patent: 5726023 (1998-03-01), Cheever
patent: 5747332 (1998-05-01), Wallen et al.
patent: 5830464 (1998-11-01), Srivastava
patent: 5858192 (1999-01-01), Becker
patent: 5888795 (1999-03-01), Hamilton
patent: 5891432 (1999-04-01), Hoo
patent: 5961979 (1999-10-01), Srivastava
patent: 5981706 (1999-11-01), Wallen et al.
patent: 6015567 (2000-01-01), Hudziak
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6066716 (2000-05-01), Wallen et al.
patent: 6156302 (2000-12-01), Srivastava
patent: 6159708 (2000-12-01), Sogo et al.
patent: 6162436 (2000-12-01), Srivastava
patent: 6187312 (2001-02-01), Srivastava
patent: 6268213 (2001-07-01), Samulski
patent: 6322790 (2001-11-01), Srivastava
patent: 6331299 (2001-12-01), Rothman et al.
patent: 6403095 (2002-06-01), Srivastava et al.
patent: 6451316 (2002-09-01), Srivastava et al.
patent: 7157089 (2007-01-01), Mizzen
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/10000 (1997-03-01), None
patent: WO 97/10001 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/23735 (1998-04-01), None
patent: WO 98/34641 (1998-08-01), None
patent: WO 98/35705 (1998-08-01), None
patent: WO 99/07860 (1999-02-01), None
patent: WO 00/44899 (2000-08-01), None
Oh et al (Journal of Biological chemistry, 1997, vol. 272, pp. 31636-31640).
Ikeda et al (BBRC, 1997, vol. 230, pp. 94-99).
Lin et al (Molecular biology of the Cell, 1993, vol. 4, pp. 1109-1119).
Santos et al (American Journal of Physiology, 1998, vol. 274, pp. F1054-F1061).
Lee-Yoon et al (Journal of Biological Chemistry, 1995, vol. 270, pp. 15725-15733).
Bachman et al., Journal of Immunology, 2005,vol. 175, pp. 4677-4685.
Bargmann, C.I. et al., “The neu oncogene encodes an epidermal growth factor receptor-related protein,” 1986, Nature, 319(16):226-230.
Bargmann, C.I. et al., “Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p185,” 1986, Cell, 45:649-657.
Blachere, N.E. et al., “Heat Shock Protein-Based Cancer Vaccines and Related Thoughts on Immunogenicity of Human Tumors,” Cancer Biology, 1995, vol. 6: 349-355.
Blachere, N.E. et al., “Heat Shock Protein Vaccines Against Cancer,” Jnl. of Immunology, 1993, 14(4): 352-356.
Boorstein, W.R. et al., “Molecular Evolution of the HSP70 Multigene Family,” 1994, J Mol Evol, 38:1-17.
Chen, C-H. et al., “Enhancement of DNA Vaccine Potency by Linkage of Antigen Gene to an HSP70 Gene,” Cancer Research, 2000, vol. 60: 1035-1042.
X. Chen et al., “The 170 kCa glucose regulated stress protein is a large HSP70-HSP110-like protein of the endoplasmic reticulum,” XP-002060249, 1996, FEBS Letters, 380:68-72.
Coler, R.N., “Molecular Cloning and Immunologic Reactivity of a Novel Low Molecular Mass Antigen ofMycobacterium tuberculosis1,” 1998, J Immun, 161(5):2356-2364.
Dillon, D.C. et al., “Molecular Characterization and Human T-Cell Responses to a Member of a NovelMycobacterium tuberculosis,” XP-002143391, 1999, Infection and Immunity, pp. 2941-2950.
Disis, M.L. et al., “Generation of Immunity to the HER-2
euOncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine,” Clinical Cancer Research, 1999, vol. 5: 1289-1297.
Dong et al., Pharmaceutical Biotechnology, 1995, vol. 6, pp. 625-643.
Donnelly et al., “DNA Vaccines: Progress and Challenges”, Journal & Immunology, 2005, 175(2):633-639.
Efferson et al., Anticancer Research, 2005, vol. 25, pp. 715-724.
Hatayama, T. et al., “Association of HSP105 with HSC70 in High Molecular Mass Complexes in Mouse FM3A Cells,” 1998, Biochem and Biophys Res Comm, 248:395-401.
Heath, Pharmaceutical Biotechnology, 1995, vol. 6, pp. 645-658.
Janetzki, S. et al., “Immunization of Cancer Patients with Autologous Cancer-Derived Heat Shock Protein gp96 Preparations: A Pilot Study,” International Jnl. of Cancer, 2000, vol. 88: 232-238.
Jindal, S., “Heat shock proteins: applications in health and disease,”1996, TB Tech, vol. 14, p. 5.
Li, Z., “Priming of T Cells by Heat Shock Protein-Peptide Complexes as the Basis of Tumor Vaccines,” Seminars in Immunology, 1997, vol. 9: 315-322.
Manjili, M.H. et al., “Development of a Recombinant HSP110-HER-2
euVaccine Using the Chaperoning Properties of HSP110,” Cancer Research, 2002, vol. 62: 1737-1742.
Manjili, M.H et al., “Immunotherapy of Cancer Using Heat Shock Proteins,” Frontiers in Bioscience, 2002, vol. 7: d43-52.
Menoret, A. et al., “Heat-Shock Protein-Based Anticancer Immunotherapy: An Idea Whose Time Has Come,” Seminars in Oncology, 1998, 25(6): 654-660.
Moroi, Y. et al., “Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides Complexed to Heat Shock Protein 70,” PNAS, 2000, 97(7): 3485-3490.
Mosley, P., “Stress proteins and the immune response”, Immunopharmacology, vol. 48, Jul. 2000, pp. 299-302.
Oh, H. et al., “The Chaperoning Activity of hsp110,” 1999, J of Biol Chem, 274(22):15712-15718.
Oh, H.J. et al., “hsp110 Protects Heat-denatured Proteins and Confers Cellular Thermoresistance,” 1997, J Biol Chem, 272(5):31636-31640.
Palleros, D.R. et al., “hsp70-Protein Complexes,” XP-002130137, 1994, 269(18):13107-13114.
Pzepiorka, D. et al., “Heat Shock Protein-Peptide Complexes as Immunotherapy for Human Cancer,” Molecular Medicine Today, 1998, 4(11): 478-484.
Rakhmilevich, A.L. et al., “Effective Particle-mediated Vaccination Against Mouse Melanoma by Coadministration of Plasmid DNA Encoding Gp100 and Granulocyte-Macrophage Colony-Stimulating Factor,” Cancer Research, 2001, 7: 952-961.
Shyy, T. et al., “Effect of Growth State and Heat Shock on Nucleolar Localization of the 110,000-Da Heat Shock Protein in Mouse Embryo Fibroblasts1,” 1986, Cancer Research, 46:4738-4745.
Spee, P., “Identification of Novel Peptide Binding Proteins in the Endoplasmic Reticulum: ERp72, Calnexin, and grp 170”, Biochemistry, 1999, V. 38, pp. 10559-10566.
Srivastava, P.K., “Purification of Heat Shock Protein-Peptide Complexes for Use in Vaccination Against Cancers and Intracellular Pathogens,” Methods: A Companion to Methods in Enzymology, 1997, vol. 12: 165-171.
Subject, J., “The 110 kDa Heat-shock Protein and the 170 kDa Glucose Regulated Protein”, 1992, vol. 2, pp. 986-991.
Suzue, K., et al., “Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway,” 1997, Proc Natl Acad Sci USA, 94:13146-13151.
Tamura, Y. et al., “Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations,” Science, 1997, vol. 278: 117-120.
Udono, H. et al., “Generation of Cytotoxic T Lymphocytes by MHC Class I Ligands Fused to Heat Shock Cognate Protein 70,” International Immunology, 2001, 13(10): 1233-1242.
Vanaja, D.K. et al., “Tumor Prevention and Antitumor Immunity with Heat Shock Protein 70 Induced by 15-Deoxy-Δ12,14-prostaglandin J2in
Henderson Robert A.
Kazim Latif
Manjili Masoud H.
Repasky Elizabeth A.
Subjeck John R.
Canady Karen S.
canady + Lortz LLP
Canella Karen
Health Research , Inc.
LandOfFree
Stress protein compositions and methods for prevention and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stress protein compositions and methods for prevention and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stress protein compositions and methods for prevention and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4266396